Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Achieve Clinical Research
mi
from
Birmingham, AL
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Axis Clinical Trials
mi
from
Los Angeles, CA
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Axis Clinical Trials
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
National Research Institute
mi
from
Los Angeles, CA
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
National Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Infosphere Clinical Research, Inc.
mi
from
West Hills, CA
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Infosphere Clinical Research, Inc.
mi
from
West Hills, CA
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Clinical Research of South Florida
mi
from
Coral Gables, FL
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Clinical Research of South Florida
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Med Research Of Florida, LLC
mi
from
Miami, FL
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Med Research Of Florida, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
High Point Clinical Trials Center
mi
from
High Point, NC
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
High Point Clinical Trials Center
mi
from
High Point, NC
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Clinical Trial Network
mi
from
Houston, TX
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Clinical Trial Network
mi
from
Houston, TX
Click here to add this to my saved trials
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/15/2016
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/15/2016
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Click here to add this to my saved trials
Effect of Diabetes Mellitus on Cholesterol Metabolism
Effect of Diabetes Mellitus on Cholesterol Absorption, Synthesis and Statin Efficacy
Status: Enrolling
Updated:  3/16/2016
Medical College of Wisconsin/ Froedtert Hospital
mi
from
Milwaukee, WI
Effect of Diabetes Mellitus on Cholesterol Metabolism
Effect of Diabetes Mellitus on Cholesterol Absorption, Synthesis and Statin Efficacy
Status: Enrolling
Updated: 3/16/2016
Medical College of Wisconsin/ Froedtert Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Walnut Consumption, Endothelial Function, and Biomarkers
Walnut Consumption, Endothelial Function, and Plasma Adipokines in Subjects With Diabetes or Coronary Disease: a Pilot Trial
Status: Enrolling
Updated:  3/16/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Walnut Consumption, Endothelial Function, and Biomarkers
Walnut Consumption, Endothelial Function, and Plasma Adipokines in Subjects With Diabetes or Coronary Disease: a Pilot Trial
Status: Enrolling
Updated: 3/16/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Exenatide on Liver and Heart Fat and Inflammation
Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/16/2016
Baylor College of Medicine
mi
from
Houston, TX
Effect of Exenatide on Liver and Heart Fat and Inflammation
Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/16/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1160.129.32023 Boehringer Ingelheim Investigational Site
mi
from
Gulf Shores, AL
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1160.129.32023 Boehringer Ingelheim Investigational Site
mi
from
Gulf Shores, AL
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1264.3.01006 Boehringer Ingelheim Investigational Site
mi
from
Norwalk, CA
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1264.3.01006 Boehringer Ingelheim Investigational Site
mi
from
Norwalk, CA
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1245.20.10038 Boehringer Ingelheim Investigational Site
mi
from
Northglenn, CO
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1245.20.10038 Boehringer Ingelheim Investigational Site
mi
from
Northglenn, CO
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1275.1.01110 Boehringer Ingelheim Investigational Site
mi
from
Coral Gables, FL
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1275.1.01110 Boehringer Ingelheim Investigational Site
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1276.1.10024 Boehringer Ingelheim Investigational Site
mi
from
Oldsmar, FL
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1276.1.10024 Boehringer Ingelheim Investigational Site
mi
from
Oldsmar, FL
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1275.9.01001 Boehringer Ingelheim Investigational Site
mi
from
Palm Coast, FL
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1275.9.01001 Boehringer Ingelheim Investigational Site
mi
from
Palm Coast, FL
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1264.3.01019 Boehringer Ingelheim Investigational Site
mi
from
Port Orange, FL
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1264.3.01019 Boehringer Ingelheim Investigational Site
mi
from
Port Orange, FL
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1245.28.10033 Boehringer Ingelheim Investigational Site
mi
from
Blue Ridge, GA
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1245.28.10033 Boehringer Ingelheim Investigational Site
mi
from
Blue Ridge, GA
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1218.75.056 Boehringer Ingelheim Investigational Site
mi
from
Marietta, GA
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1218.75.056 Boehringer Ingelheim Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1199.15.10004 Boehringer Ingelheim Investigational Site
mi
from
Savannah, GA
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1199.15.10004 Boehringer Ingelheim Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1275.9.01019 Boehringer Ingelheim Investigational Site
mi
from
Methuen, MA
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1275.9.01019 Boehringer Ingelheim Investigational Site
mi
from
Methuen, MA
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
205.452.01221 Boehringer Ingelheim Investigational Site
mi
from
Troy, MI
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
205.452.01221 Boehringer Ingelheim Investigational Site
mi
from
Troy, MI
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Omaha, NE
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1275.9.01007 Boehringer Ingelheim Investigational Site
mi
from
Newington, NH
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1275.9.01007 Boehringer Ingelheim Investigational Site
mi
from
Newington, NH
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1218.75.038 Boehringer Ingelheim Investigational Site
mi
from
Asheboro, NC
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1218.75.038 Boehringer Ingelheim Investigational Site
mi
from
Asheboro, NC
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
205.452.01101 Boehringer Ingelheim Investigational Site
mi
from
Burlington, NC
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
205.452.01101 Boehringer Ingelheim Investigational Site
mi
from
Burlington, NC
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1245.28.10006 Boehringer Ingelheim Investigational Site
mi
from
Shelby, NC
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1245.28.10006 Boehringer Ingelheim Investigational Site
mi
from
Shelby, NC
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1199.15.10020 Boehringer Ingelheim Investigational Site
mi
from
Winston-Salem, NC
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1199.15.10020 Boehringer Ingelheim Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
205.452.01309 Boehringer Ingelheim Investigational Site
mi
from
Dayton, OH
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
205.452.01309 Boehringer Ingelheim Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
205.452.01189 Boehringer Ingelheim Investigational Site
mi
from
Corvallis, OR
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
205.452.01189 Boehringer Ingelheim Investigational Site
mi
from
Corvallis, OR
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1200.32.2609 Boehringer Ingelheim Investigational Site
mi
from
Corpus Christi, TX
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1200.32.2609 Boehringer Ingelheim Investigational Site
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated:  3/17/2016
1275.9.61009 Boehringer Ingelheim Investigational Site
mi
from
Liverpool,
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.
Status: Enrolling
Updated: 3/17/2016
1275.9.61009 Boehringer Ingelheim Investigational Site
mi
from
Liverpool,
Click here to add this to my saved trials
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated:  3/18/2016
Albert Lea Medical Center
mi
from
Albert Lea, MN
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated: 3/18/2016
Albert Lea Medical Center
mi
from
Albert Lea, MN
Click here to add this to my saved trials
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated:  3/18/2016
Mayo Clinic Kasson
mi
from
Kasson, MN
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated: 3/18/2016
Mayo Clinic Kasson
mi
from
Kasson, MN
Click here to add this to my saved trials
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated:  3/18/2016
Mayo Clinic Health System- Immanual St. Joseph's
mi
from
Mankato, MN
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated: 3/18/2016
Mayo Clinic Health System- Immanual St. Joseph's
mi
from
Mankato, MN
Click here to add this to my saved trials
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated:  3/18/2016
Hennepin County Medical Center
mi
from
Minneapolis, MN
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated: 3/18/2016
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated:  3/18/2016
Park Nicollet Institute
mi
from
St. Louis Park, MN
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated: 3/18/2016
Park Nicollet Institute
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated:  3/18/2016
Mayo Clinic Health System-Franciscan Healthcare
mi
from
La Crosse, WI
Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Status: Enrolling
Updated: 3/18/2016
Mayo Clinic Health System-Franciscan Healthcare
mi
from
La Crosse, WI
Click here to add this to my saved trials
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/22/2016
1199.15.10028 Boehringer Ingelheim Investigational Site
mi
from
New Haven, CT
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/22/2016
1199.15.10028 Boehringer Ingelheim Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/22/2016
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/22/2016
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials